<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000405" GROUP_ID="NEONATAL" ID="642399090718244051" MERGED_FROM="" MODIFIED="2008-10-31 21:09:20 +0100" MODIFIED_BY="Diane Haughton" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Short title (no longer in use): Enteral antibiotics for NEC prophylaxis&lt;/p&gt;&lt;p&gt;Do not remove&lt;br&gt;CL 1/01 update&lt;br&gt;CL 3/02 update&lt;/p&gt;&lt;p&gt;sent to Bury June 24/04&lt;/p&gt;&lt;p&gt;sent 10/05&lt;/p&gt;&lt;p&gt;CL 1/07 (minor update)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-09-18 11:00:29 -0400" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2008-10-31 21:09:20 +0100" MODIFIED_BY="Diane Haughton">
<TITLE>Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants</TITLE>
<CONTACT MODIFIED="2008-10-31 21:09:20 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="5050" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Tudehope</LAST_NAME><POSITION>Director of Neonatology, Professor in Perinatal Paediatrics</POSITION><EMAIL_1>dtudehop@mater.org.au</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neonatology</DEPARTMENT><ORGANISATION>Mater Misericordiae Mothers' Hospital</ORGANISATION><ADDRESS_1>Raymond  Terrace</ADDRESS_1><CITY>South Brisbane</CITY><ZIP>4101</ZIP><REGION>QLD</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7  3840 8441</PHONE_1><PHONE_2>+61 7 3840 8111</PHONE_2><FAX_1>+ 61 7 3840 1949</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-10-31 21:09:20 +0100" MODIFIED_BY="Diane Haughton"><PERSON ID="4500" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Richard Graham</FIRST_NAME><LAST_NAME>Bury</LAST_NAME><POSITION>Director</POSITION><ADDRESS><DEPARTMENT>Neonatal Services</DEPARTMENT><ORGANISATION>Royal Hobart Hospital</ORGANISATION><ADDRESS_1>Liverpool St.</ADDRESS_1><CITY>Hobart</CITY><ZIP>7000</ZIP><REGION>Tasmania</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>61 3 62228308 ext: 8220</PHONE_1><PHONE_2>61 3 62313781</PHONE_2><FAX_1>61 3 62342264</FAX_1></ADDRESS></PERSON><PERSON ID="5050" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Tudehope</LAST_NAME><POSITION>Director of Neonatology, Professor in Perinatal Paediatrics</POSITION><EMAIL_1>dtudehop@mater.org.au</EMAIL_1><ADDRESS><DEPARTMENT>Division of Neonatology</DEPARTMENT><ORGANISATION>Mater Misericordiae Mothers' Hospital</ORGANISATION><ADDRESS_1>Raymond  Terrace</ADDRESS_1><CITY>South Brisbane</CITY><ZIP>4101</ZIP><REGION>QLD</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 7  3840 8441</PHONE_1><PHONE_2>+61 7 3840 8111</PHONE_2><FAX_1>+ 61 7 3840 1949</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-09-18 10:56:04 -0400" MODIFIED_BY="Yolanda Montagne" NOTES="&lt;p&gt;Minor update: 31/08/06&lt;/p&gt;&lt;p&gt;New studies sought but none found: 01/08/06&lt;/p&gt;&lt;p&gt;Reformatted: 09/09/99&lt;/p&gt;" NOTES_MODIFIED="2008-09-18 10:56:04 -0400" NOTES_MODIFIED_BY="Yolanda Montagne">
<UP_TO_DATE>
<DATE DAY="31" MONTH="8" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="8" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="8" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-18 10:43:20 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="18" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-18 10:43:20 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-09-18 10:43:20 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="8" YEAR="2006"/>
<DESCRIPTION>
<P>This review is an update of the previous review cited as: Bury RG, Tudehope D. Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants, published in The Cochrane Library, Issue 3, 2002 (Bury 2002).<BR/>
<BR/>No new trials have been found since the last substantive update in September 2000. The conclusion remains unchanged. Although prophylactic enteral antibiotics reduce the incidence of necrotizing enterocolitis in low birth weight infants, their use for this purpose may increase the development of resistant bacteria.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="1" MONTH="9" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Mater Mother's Hospital, Brisbane</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Royal Hobart Hospital, Tasmania</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centre for Clinical Studies - Women's and Children's Health, Mater Hospital, South Brisbane, Queensland</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Health and Ageing, Commonwealth Government, Canberra ACT</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Centre for Perinatal Health Services Research, University of Sydney</NAME>
<COUNTRY CODE="AU">Australia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-18 10:43:36 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-18 10:43:34 -0400" MODIFIED_BY="[Empty name]">Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-18 10:43:36 -0400" MODIFIED_BY="[Empty name]">
<P>Not enough evidence to support administering antibiotics through a feeding tube for low birth weight and new born babies to prevent necrotizing enterocolitis. Necrotizing enterocolitis (NEC) is a serious disease that affects the bowel in the first few weeks of life. The cause is unknown but milk feeding and bacteria may contribute. NEC is more common in preterm babies, possibly because of reduced immunity. Oral antibiotics have been used to prevent NEC but there are concerns about the possible adverse effects of oral antibiotics such as resistance to bacteria. The review of trials found there was not enough evidence to support the use of antibiotics to prevent NEC in preterm and low birth weight babies. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Necrotizing enterocolitis (NEC) is the most common gastrointestinal problem of preterm neonates. There have been reports published suggesting that the use of enteral antibiotics may be effective as prophylaxis. This systematic review was undertaken to clarify the issue.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the benefits and harms of enteral antibiotic prophylaxis for necrotizing enterocolitis in low birth weight and preterm infants.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Searches were made of the Oxford Database of Perinatal Trials, Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2006), MEDLINE (1966 - July 2006), EMBASE (1988 - July 2006) and CINAHL (1982 - July 2006) previous reviews with cross references, abstracts, conference and symposia proceedings, expert informants and journal hand searching in the fields of neonatal pediatrics and microbiology.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized or quasi-randomized controlled trials where enteral antibiotics were used as prophylaxis against NEC in LBW (&lt; 2500 g) and/or preterm (&lt; 37 weeks gestation) infants.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>The standard method of the Cochrane Collaboration and its Neonatal Review Group was used. The methodological quality of each trial was reviewed by the second author who was blinded to the trial authors and institutions. Each author extracted data separately before comparison and resolution of differences. Relative risk (RR), risk difference (RD), and number needed to treat were used in the analysis.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Five eligible trials involving 456 infants were included. The administration of prophylactic enteral antibiotics resulted in a statistically significant reduction in NEC [typical RR 0.47 (0.28, 0.78); typical RD -0.10 (-0.16, -0.04); NNT 10 (6, 25)]. </P>
<P>There was a statistically significant reduction in NEC-related deaths [typical RR 0.32 (0.10, 0.96); typical RD -0.07 (-0.13, 0.01); NNT 14 (8, 100)]. </P>
<P>There was a trend towards a reduction in all deaths which was not significant [typical RR 0.67(0.34, 1.32)]. </P>
<P>There were no significant differences in NEC-like enteropathies (one trial only). </P>
<P>One study found a statistically significant increase in the incidence of colonization with resistant bacteria and the summary analysis of three trials gave an increase which was just significant [RR 1.73 (1.00, 2.97); RD 0.07 (0.00, 0.13)]. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Evidence suggests that oral antibiotics reduce the incidence of NEC in low birth weight infants. However concerns about adverse outcomes persist, particularly related to the development of resistant bacteria. To address this question further, a large trial would be required with a sample size sufficient to examine all the important benefits and harms. Adverse outcomes associated with infection should be evaluated, and microbiological studies looking for the development of resistant bacteria should be undertaken</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<P>The pathogenesis of necrotizing enterocolitis (NEC) is multi-factorial and any unifying hypothesis remains unproven (<LINK REF="REF-Bauer-1992" TYPE="REFERENCE">Bauer 1992</LINK>). Hypoxic-ischemic bowel injury with intestinal mucosal disruption in the presence of enteral feeding and bacterial colonization may contribute to the development of NEC. Infants who are preterm or of low birth weight (LBW) have an increased susceptibility, possibly as a result of a compromised immune system.</P>
<P>There have been reports of the effectiveness of using enteral antibiotics as prophylaxis against NEC in low birth weight and preterm infants. There are concerns about the strength of evidence of the effectiveness and possible harmful effects of the use of oral antibiotics. These harmful effects include the development of bacterial resistance and other neonatal complications.</P>
<P>This review updates an earlier version published in the Cochrane Library (<LINK REF="REF-Bury-2000" TYPE="REFERENCE">Bury 2000</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the benefits and harms of enteral antibiotic prophylaxis for NEC in LBW and preterm infants.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized or quasi-randomized trials where enteral antibiotics were used as prophylaxis against NEC in LBW (&lt; 2500 g) and/or preterm (&lt; 37 weeks gestation) infants were considered for this review.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>LBW and/or preterm infants at risk for the development of NEC</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Enteral antibiotics or placebo as prophylaxis against NEC</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>The primary outcome measure was the incidence of NEC. NEC was defined as: Clinical evidence of abdominal distension and feed intolerance plus radiological evidence of pneumatosis intestinalis with or without portal venous gas and pneumoperitoneum. <BR/> <BR/>Secondary outcome measures include:<BR/>
</P>
<UL>
<LI>Death from NEC</LI>
<LI>All deaths</LI>
<LI>NEC-like enteropathies</LI>
<LI>Colonization with resistant bacteria</LI>
</UL>
<P>
<BR/>Death from NEC was defined as death where the primary cause was attributed to NEC. NEC-like enteropathy was defined as clinical evidence of abdominal distension, feed intolerance and blood in the stools in the absence of any defined X-ray abnormalities.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>The standard search strategy for the Cochrane Neonatal review Group was used. This included searches of electronic databases: Oxford Database of Perinatal Trials, Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 3, 2006), MEDLINE (1966 - July 2006), EMBASE (1988 - July 2006) and CINAHL (1982 - July 2006) using MeSH terms: enterocolitis necrotising; antibiotics; infant low birth weight; infant newborn; infant premature; controlled clinical trials; randomized-controlled trials; and text terms: necrotizing enterocolitis; enterocolitis; antibiotics; low birth weight infant; newborn infant; premature infant; preterm infant and previous reviews with cross references, abstracts, conference and symposia proceedings, expert informants and journal hand searching in the fields of neonatal pediatrics and microbiology. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Criteria and methods used to assess the methodological quality of included trials:<BR/>The standard method of the Cochrane Collaboration and its Neonatal Review Group was used. The methodological quality of each trial was reviewed by the second author who was blinded to the trial authors and institutions.</P>
<P>Methods used to collect data from the included trials:<BR/>Each author extracted data separately before comparison and resolution of differences.</P>
<P>Methods used to synthesize data:<BR/>Standard method of the Neonatal Review Group with the use of relative risk (RR), risk difference (RD), and their 95% confidence intervals. The number needed to treat (NNT) was calculated as 1/RD. Subgroup analyses were performed a posteriori, limited to the trials that used random allocation. The I<SUP>2</SUP> statistic was used to examine heterogeneity.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<P>Ten potentially relevant studies were identified. Five trials were excluded from the final analysis. One (<LINK REF="STD-Brantley-1980" TYPE="STUDY">Brantley 1980</LINK>) was not a randomized or quasi-randomized trial. Another (<LINK REF="STD-McCaffree-1975" TYPE="STUDY">McCaffree 1975</LINK>) was an abstract consisting of an interim report of a trial in progress, but with insufficient data for analysis. In two trials (<LINK REF="STD-Millar-1992" TYPE="STUDY">Millar 1992</LINK>; <LINK REF="STD-Fast-1994" TYPE="STUDY">Fast 1994</LINK>) there was no control arm which received no treatment. The last (<LINK REF="STD-Faix-1988" TYPE="STUDY">Faix 1988</LINK>) was a treatment trial in which the babies already had NEC at entry.</P>
<P>Among the five trials included, involving a total of 456 infants, four enrolled very low birth-weight infants and one (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>) enrolled infants of less than 2250 grams and less than 36 weeks gestational age at birth. Two studies (<LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>; <LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>) included other infants with specified risk factors for developing necrotizing enterocolitis, and reported on at least one relevant clinical outcome. Additional information was obtained on NEC-related deaths from Siu (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>).</P>
<P>All trials used oral antibiotics prophylactically, and the primary outcome, incidence of NEC, was reported in all trials. Two studies used enteral gentamicin (<LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>; <LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>) and two studies used enteral kanamycin (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>; <LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>). One study used enteral vancomycin (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>). Infants entered the trial on day one (<LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>), day two (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>), day three (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>), and at a mean of 7.1 days (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>). The age at entry was not specified in one trial (<LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>).</P>
<P>A full description of each of the studies is included in the Table: Characteristics of Included Studies.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<P>In four trials, random allocation to treatment groups was used (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>; <LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>; <LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>; <LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>). In one (<LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>), randomization was by blind card draw in the hospital pharmacy whilst <LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK> used random assignment by computer. The method of randomization was not specified by <LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>; <LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>. One trial (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>) used quasi-random allocation (odd or even hospital record number).</P>
<P>Blinding of the intervention was achieved in three trials (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>; <LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>; <LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>) and, probably, in a fourth (<LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>).</P>
<P>None of the trials described exclusions after randomization.</P>
<P>Blinding of the outcome measurement was ensured in all trials except for <LINK REF="STD-Rowley-1978" TYPE="STUDY">Rowley 1978</LINK>, where this is uncertain.</P>
<P>Details of the methodologic quality assessments are given in the Table: Characteristics of Included Studies.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<P>
<B>Comparison 01: Enteral aminoglycoside versus control (all studies)<BR/>Outcome 01: NEC<BR/>
</B>The administration of prophylactic enteral antibiotics produced a significant overall reduction in NEC [typical RR 0.47 (0.28, 0.78); typical RD -0.10 (-0.16, -0.04); NNT 10 (6, 25)].<BR/>In the subgroup analysis limited to the three trials that used random allocation and assessed this outcome, there was a similar significant reduction in NEC [typical RR 0.52 (0.31,0.88); typical RD -0.09 (-0.16, -0.02); NNT 11 (6, 50)].</P>
<P>
<B>Outcome 02: All deaths</B>
<BR/>Two trials (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>; <LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>) reported all deaths. Although there was a reduction in deaths in the treatment group this was not statistically significant [typical RR 0.67 (0.34, 1.32)].</P>
<P>
<B>Outcome 03: NEC-related deaths<BR/>
</B>Two trials (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>; <LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK> ) reported NEC-related deaths. Additional information was obtained on NEC-related deaths from <LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>. There was a reduction in NEC-related deaths which was statistically significant [typical RR 0.32 (0.10, 0.96); typical RD -0.07 (-0.13, 0.01); NNT 14 (8, 100)].</P>
<P>
<B>Outcome 04: NEC-like enteropathies</B>
<BR/>Only one trial (<LINK REF="STD-Grylack-1978" TYPE="STUDY">Grylack 1978</LINK>) reported on this outcome and there was a trend towards a reduction but this was not statistically significant.</P>
<P>
<B>Outcome 05: Colonization with resistant bacteria</B>
<BR/>
<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK> evaluated the development of antibiotic resistance of gram negative organisms to kanamycin during the study period of 24 days. There was a significant increase in resistance in treated compared with control infants [RR 1.96 (1.10, 3.48)] but no increase in resistance in general nursery cultures. <LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK> also assessed antibiotic resistance and found no difference in treated compared to control infants. Combining these studies gives an increase that is just statistically significant [typical RR 1.73 (1.00, 2.97); typical RD 0.07 (0.00, 0.13)]. No evidence of vancomycin resistance was found by Siu (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>) from routine microbiological surveillance or from specimens obtained for sepsis screening during the study. However a significant change in stool flora occurred with a predominant growth of gram negative organisms and yeasts demonstrated immediately and four weeks after vancomycin prophylaxis.</P>
<P>Systemic absorption of the enterally administered antibiotic was evaluated in one study (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>). Blood levels of kanamycin were found to be undetectable (&lt; 0.5 micrograms/ml).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-09-18 10:43:42 -0400" MODIFIED_BY="[Empty name]">
<P>Only one study is recent (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>). The other relatively small studies were conducted about 20 years ago when trial methodology and reporting were less rigorous and the clinical setting in neonatal units was different. Indications for enrollment varied between studies. Five trials were included, one of which was quasi-randomized (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>).</P>
<P>Although all trials reported on NEC outcome there was limited reporting of other outcomes, particularly possible harms of treatment. Only two studies reported all deaths, raising some concern about bias in outcomes dependent on survival. Systemic absorption of the antibiotic was evaluated in one study (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>).</P>
<P>Only one study (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>) provided the information on the type of feed given to infants in each arm of the study and in those infants developing NEC. No conclusions could be drawn in view of the small numbers involved.</P>
<P>The development of bacterial resistance was evaluated in three studies (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>; <LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>, <LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>). The results varied between the studies. One (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>) found no difference in bacterial resistance in the treatment or placebo group, another (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>) found an increase in the treatment group, while the third (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>) found no evidence of bacterial resistance developing in either group. The duration of treatment may have had an effect on the development of bacterial resistance since the trial which found increased resistance (<LINK REF="STD-Boyle-1978" TYPE="STUDY">Boyle 1978</LINK>) used oral kanamycin for 24 days, while the other two used oral kanamycin for 21 days (<LINK REF="STD-Egan-1976" TYPE="STUDY">Egan 1976</LINK>) and oral vancomycin for 7 days (<LINK REF="STD-Siu-1998" TYPE="STUDY">Siu 1998</LINK>) respectively.</P>
<P>Other trials concerning prevention of NEC have tested immunoglobulins and various combinations of antibiotics. <LINK REF="STD-Fast-1994" TYPE="STUDY">Fast 1994</LINK> compared oral gentamicin with an oral IgG/IgA mixture. <LINK REF="STD-Millar-1992" TYPE="STUDY">Millar 1992</LINK> compared parenteral vancomycin and aztreonam compared with parenteral vancomycin and gentamicin.</P>
<P>Several Cochrane reviews examine other interventions for the prevention of NEC in preterm infants; human milk compared with formula for feeding (<LINK REF="REF-Henderson-2001a" TYPE="REFERENCE">Henderson 2001a</LINK>; <LINK REF="REF-Henderson-2001b" TYPE="REFERENCE">Henderson 2001b</LINK>), rapid versus slow rate of advancement of feedings (<LINK REF="REF-Kennedy-1998" TYPE="REFERENCE">Kennedy 1998</LINK>; <LINK REF="REF-Kennedy-2000" TYPE="REFERENCE">Kennedy 2000</LINK>), oral immunoglobulin (<LINK REF="REF-Foster-2004" TYPE="REFERENCE">Foster 2004</LINK>) and arginine supplementation (<LINK REF="REF-Shah-2004" TYPE="REFERENCE">Shah 2004</LINK>). Trials of probiotics to prevent neonatal infection and NEC appear promising and are being reviewed (<LINK REF="REF-AlFaleh-2005" TYPE="REFERENCE">AlFaleh 2005</LINK>).</P>
<P>Currently, there is evidence to suggest that oral antibiotics are prophylactic against NEC in low birth weight infants. However, there are concerns about harms and to address this question further, a large trial conducted in selected babies at increased risk for NEC would be required. For example, to demonstrate a 50% relative risk reduction in a population with an anticipated NEC risk of 10%, more than 500 patients in each arm would be required. Babies now at risk of NEC include many who are of substantially lower birth weight and gestational age than those enrolled in previous trials. It would be important to clearly define the groups at risk and to stratify by gestational age. An evaluation of systemic absorption of enterally administered antibiotics should be included.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>There is insufficient evidence to support the use of prophylactic enteral antibiotics as prophylaxis for NEC in clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>To address this question further a large trial would be required with a sample size sufficient to examine all the important benefits and harms. Extended surveillance would be necessary to determine whether antibiotic resistance had emerged. Adverse outcomes associated with infection, particularly with resistant bacteria, should be evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>Dr Siu kindly provided additional data from their study.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None<BR/> </P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Both reviewer authors assessed the trials for eligibility, quality, and extracted data independently. The review was written by RGB with the editorial assistance of DT.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-09-18 11:00:29 -0400" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Boyle-1978" NAME="Boyle 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Boyle R, Nelson JS, Stonestreet BS, Peter G, Oh W. Alterations in stool flora resulting from oral kanamycin prophylaxis of necrotizing enterocolitis. J Pediatr 1978;93:857-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boyle R, Nelson JS, Stonestreet BS, Peter G, Oh W</AU>
<TI>Alterations in stool flora resulting from oral kanamycin prophylaxis of necrotizing enterocolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1978</YR>
<VL>93</VL>
<PG>857-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Egan-1976" NAME="Egan 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Egan EA, Mantilla G, Nelson RM, Eitzmann DV. A prospective controlled trial of oral kanamycin in the prevention of neonatal necrotizng enterocolitis. J Pediatr 1976;89:467-470.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Egan EA, Mantilla G, Nelson RM, Eitzmann DV</AU>
<TI>A prospective controlled trial of oral kanamycin in the prevention of neonatal necrotizng enterocolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1976</YR>
<VL>89</VL>
<PG>467-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grylack-1978" NAME="Grylack 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Grylack LJ, Scanlon JW. Oral gentamicin therapy in the prevention of neonatal necrotizing enterocolitis. A controlled double-blind trial. Am J Dis Child 1978;132:1192-1194.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grylack LJ, Scanlon JW</AU>
<TI>Oral gentamicin therapy in the prevention of neonatal necrotizing enterocolitis. A controlled double-blind trial</TI>
<SO>American Journal of Diseases of Children</SO>
<YR>1978</YR>
<VL>132</VL>
<PG>1192-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rowley-1978" NAME="Rowley 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Rowley MP , Dahlenburg GW. Gentamicin in prophylaxis of neonatal necrotizing enterocolitis. Lancet 1978;ii:532.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rowley MP, Dahlenburg GW</AU>
<TI>Gentamicin in prophylaxis of neonatal necrotizing enterocolitis</TI>
<SO>Lancet</SO>
<YR>1978</YR>
<VL>ii</VL>
<PG>532</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Siu-1998" NAME="Siu 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siu YK, Ng PC, Fung SC, Lee CH, Wong MY, Fok TF, So KW, Cheung KL, Wong W, Cheng AF</AU>
<TI>Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants</TI>
<SO>Archives of Disease in Childhood Fetal Neonatal Ed</SO>
<YR>1998</YR>
<VL>79</VL>
<PG>F105-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Brantley-1980" NAME="Brantley 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;Brantley VE , Hiatt IM, Hegyi T. The effectiveness of oral gentamicin in reducing the incidence of necrotizing enterocolitis (NEC) in treated and control infants. Pediatr Res 1980;14:592 (Abstract).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brantley VE, Hiatt IM, Hegyi T</AU>
<TI>The effectiveness of oral gentamicin in reducing the incidence of necrotizing enterocolitis (NEC) in treated and control infants [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1980</YR>
<VL>14</VL>
<PG>592 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faix-1988" NAME="Faix 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Faix RG, Polley TZ, Grasela TH. A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis. J Pediatr 1988;112:271-277&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Faix RG, Polley TZ, Grasela TH</AU>
<TI>A randomized, controlled trial of parenteral clindamycin in neonatal necrotizing enterocolitis</TI>
<SO>Journal of Pediatrics</SO>
<YR>1988</YR>
<VL>112</VL>
<PG>271-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fast-1994" NAME="Fast 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Fast C , Rosegger H. Necrotizing enterocolitis prophylaxis: oral antibiotics and lyophilized enterobacteria vs oral immunoglobulins. Acta Pediatr 1994; Suppl 396:86-90.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fast C, Rosegger H</AU>
<TI>Necrotizing enterocolitis prophylaxis: oral antibiotics and lyophilized enterobacteria vs oral immunoglobulins</TI>
<SO>Acta Pediatrica</SO>
<YR>1994</YR>
<VL>Suppl 396</VL>
<PG>86-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McCaffree-1975" NAME="McCaffree 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;McCaffree MA , Fletcher AB , Avery GB . Prophylactic oral antibiotics in necrotizing enterocolitis. Pediatr Res 1975;9:307 (Abstract).&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McCaffree MA, Fletcher AB, Avery GB</AU>
<TI>Prophylactic oral antibiotics in necrotizing enterocolitis [abstract]</TI>
<SO>Pediatric Research</SO>
<YR>1975</YR>
<VL>9</VL>
<PG>307 (Abstract)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Millar-1992" NAME="Millar 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Millar MR, MacKay P, Levene M, Langdale V, Martin C. Enterobacteriaceae and neonatal necrotising enterocolitis. Arch Dis Child 1992;67:53-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Millar MR, MacKay P, Levene M, Langdale V, Martin C</AU>
<TI>Enterobacteriaceae and neonatal necrotising enterocolitis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1992</YR>
<VL>67</VL>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-09-18 11:00:29 -0400" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-09-18 11:00:29 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-AlFaleh-2005" MODIFIED="2008-09-18 11:00:29 -0400" MODIFIED_BY="[Empty name]" NAME="AlFaleh 2005" TYPE="COCHRANE_REVIEW">
<AU>AlFaleh K, Bassler D</AU>
<TI>Probiotics for prevention of mortality and morbidity in preterm infants (Protocol)</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-09-18 11:00:29 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 11:00:29 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005496   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bauer-1992" NAME="Bauer 1992" NOTES="&lt;p&gt;Bauer CR. Necrotizing enterocolitis. In: Sinclair JC, Bracken MB (eds), Effective Care of the Newborn Infant. Oxford: Oxford University Press 1992; pp 602-614.&lt;/p&gt;" TYPE="BOOK_SECTION">
<AU>Bauer CR</AU>
<TI>Necrotizing enterocolitis</TI>
<SO>Effective Care of the Newborn Infant</SO>
<YR>1992</YR>
<PG>602-14</PG>
<ED>Sinclair JC, Bracken MB</ED>
<PB>Oxford University Press</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-2004" MODIFIED="2008-09-18 10:59:34 -0400" MODIFIED_BY="[Empty name]" NAME="Foster 2004" TYPE="COCHRANE_REVIEW">
<AU>Foster J, Cole M</AU>
<TI>Oral immunoglobulin for preventing necrotizing enterocolitis in preterm and low birth-weight neonates</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-09-18 10:59:34 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 10:59:34 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001816"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Henderson-2001a" NAME="Henderson 2001a" TYPE="COCHRANE_REVIEW">
<AU>Henderson G, Anthony M, McGuire W</AU>
<TI>Formula milk versus preterm human milk for feeding preterm or low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Henderson-2001b" NAME="Henderson 2001b" TYPE="COCHRANE_REVIEW">
<AU>Henderson G, Anthony M, McGuire W</AU>
<TI>Formula milk versus term human milk for feeding preterm or low birth weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-1998" NAME="Kennedy 1998" TYPE="COCHRANE_REVIEW">
<AU>Kennedy K, Tyson J</AU>
<TI>Rapid versus slow rate of advancement of feedings for promoting growth and preventing necrotizing enterocolitis in parenterally fed low-birth-weight infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kennedy-2000" NAME="Kennedy 2000" TYPE="COCHRANE_REVIEW">
<AU>Kennedy K, Tyson J</AU>
<TI>Early versus delayed initiation of progressive enteral feedings for parenterally fed low birth weight or preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shah-2004" MODIFIED="2008-09-18 10:57:48 -0400" MODIFIED_BY="[Empty name]" NAME="Shah 2004" TYPE="COCHRANE_REVIEW">
<AU>Shah P, Shah V</AU>
<TI>Arginine supplementation for prevention of necrotising enterocolitis in preterm infants</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2008-09-18 10:57:48 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 10:57:48 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004339.pub2   "/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-09-18 10:58:49 -0400" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bury-1998" MODIFIED="2008-09-18 10:58:36 -0400" MODIFIED_BY="[Empty name]" NAME="Bury 1998" TYPE="COCHRANE_REVIEW">
<AU>Bury RG, Tudehope D</AU>
<TI>Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants</TI>
<SO>Cochrane Library</SO>
<YR>1998</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-18 10:58:36 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 10:58:36 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000405   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bury-2000" MODIFIED="2008-09-18 10:58:42 -0400" MODIFIED_BY="[Empty name]" NAME="Bury 2000" TYPE="COCHRANE_REVIEW">
<AU>Bury RG, Tudehope D</AU>
<TI>Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants</TI>
<SO>Cochrane Library</SO>
<YR>2000</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-18 10:58:42 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 10:58:42 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000405   "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bury-2002" MODIFIED="2008-09-18 10:58:49 -0400" MODIFIED_BY="[Empty name]" NAME="Bury 2002" TYPE="COCHRANE_REVIEW">
<AU>Bury G, Tudehope D</AU>
<TI>Enteral antibiotics for preventing necrotizing enterocolitis in low birthweight or preterm infants</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>3</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-09-18 10:58:49 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-09-18 10:58:49 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000405   "/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Boyle-1978">
<CHAR_METHODS>
<P>Randomized<BR/>Single centre trial<BR/>Blinding of randomization: yes<BR/>Blinding of intervention:yes<BR/>Complete follow up: yes<BR/>Blinding of outcome measurement: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>99 Infants &lt;36 weeks gestation weighing &lt;2,250 grams who were able to begin enteral or gavage feeds</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Kanamycin enteral 15mg/kg/day. Same volume of placebo given 3 times a day for 24 days or until discharge or when NEC occurred</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence of NEC<BR/>Microbiological colonisation rates</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Egan-1976">
<CHAR_METHODS>
<P>Quazi-randomized<BR/>Single unit<BR/>Blinding of randomisation: no<BR/>Blinding of intervention: no<BR/>Complete follow-up: yes<BR/>Blinding of outcome measurement: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>75 infants of Birthweight &lt; 1,500 grams<BR/>Receiving enteral feeds</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Kanamycin enteral (15 mg/kg/day in three doses) for 21 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence of NEC<BR/>All deaths<BR/>NEC-related deaths<BR/>Blood levels of kanamycin<BR/>Microbiological colonisation rates</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Grylack-1978">
<CHAR_METHODS>
<P>Randomized <BR/>Single centre trial<BR/>Blinding at randomisation: yes<BR/>Blinding of intervention: can't tell<BR/>Complete followup: yes<BR/>Blinding of outcome measurement: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>42 infants of Birthweight &lt; 1,500 grams<BR/>Any weight plus umbilical catheter<BR/>Preterm plus fetal distress, postnatal asphyxia or hypotension</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Gentamicin enteral (2.5mg/kg/day 6 hourly for 7 days)<BR/>v 5% dextrose in water (2.5mg/kg/day 6 hourly for 7 days)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence of NEC<BR/>NEC-related death<BR/>NEC-like enteropathies</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Rowley-1978">
<CHAR_METHODS>
<P>Randomized<BR/>Single centre trial<BR/>Blinding of randomization: yes<BR/>Blinding of intervention: yes<BR/>Complete follow up: yes<BR/>Blinding of outcome measurement: can`t tell</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>100 infants of Birthweight &lt;1500 grams<BR/>Umbilical arterial or venous catheters<BR/>Premature infants with fetal distress, severe hypoxia or hypotension<BR/>Apgar scores of &lt;7 at 5 minutes in infants &lt;2000 grams</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Gentamycin enteral 2.5mg/kg 6 hourly for one week. Sterile water 6 hourly for one week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence of NEC</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>This trial was described in a letter to Lancet.<BR/>No deaths or other outcomes reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Siu-1998">
<CHAR_METHODS>
<P>Double blind randomized trial at one centre.<BR/>Blinding of randomization: yes<BR/>Blinding of intervention: yes<BR/>Completeness of followup: not stated<BR/>Blinding of outcome assessment: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>140 preterm infants with birthweight<BR/>&lt;1500 grams, 48 hrs old. Excluded infants with lethal anomalies, major gastrointestinal anomalies and prior gastrointestinal surgery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Vancomycin oral 15mg per kg 8 hourly for 7 days or placebo (sterile water with one drop multivitamin per 20 ml).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Incidence of NEC, all deaths, microbial cultures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Author provided information on NEC related deaths</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Brantley-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomized or quasi-randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faix-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a prophylaxis trial. Babies had NEC at entry, and were randomised to ampicillin and gentamicin vs ampicillin, gentamicin and clindamycin.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fast-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control arm. Interim report of trial in progress. Oral gentamicin vs an oral IgG/IgA mixture.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McCaffree-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>Abstract only. Interim report of trial in progress. Insufficient data for analysis. Primary author could not be located for further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Millar-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>No control arm. In this study comparison was between vancomycin and aztreonam vs vancomycin and gentamicin, all drugs being given parenterally.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Boyle-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="NO" STUDY_ID="STD-Egan-1976">
<DESCRIPTION>
<P>C - Inadequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Grylack-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rowley-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Siu-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Enteral aminoglycoside versus control (all studies)</NAME>
<DICH_OUTCOME CHI2="6.765144084616928" CI_END="0.7801452069510512" CI_START="0.2791936646658635" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.46670290260525743" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="40" I2="40.873395304388445" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.10782455537573465" LOG_CI_START="-0.5540944407475621" LOG_EFFECT_SIZE="-0.3309594980616484" METHOD="MH" NO="1" P_CHI2="0.1488322444898751" P_Q="0.0" P_Z="0.0036483259938282727" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="225" TOTAL_2="231" WEIGHT="100.0" Z="2.907069097892728">
<NAME>NEC</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1822494681562843" CI_START="0.09785797214020377" EFFECT_SIZE="0.3401360544217687" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07270912731690526" LOG_CI_START="-1.00940378814122" LOG_EFFECT_SIZE="-0.46834733041215726" ORDER="1" O_E="0.0" SE="0.6356384830854235" STUDY_ID="STD-Boyle-1978" TOTAL_1="49" TOTAL_2="50" VAR="0.40403628117913826" WEIGHT="21.933400476396013"/>
<DICH_DATA CI_END="1.8083163172120158" CI_START="0.005927928277624357" EFFECT_SIZE="0.10353535353535354" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.25727440114153444" LOG_CI_START="-2.227097059553088" LOG_EFFECT_SIZE="-0.9849113292057768" ORDER="2" O_E="0.0" SE="1.4593320938490886" STUDY_ID="STD-Egan-1976" TOTAL_1="35" TOTAL_2="40" VAR="2.129650160137965" WEIGHT="12.661263248765048"/>
<DICH_DATA CI_END="2.1275598503971165" CI_START="0.0069606577058937864" EFFECT_SIZE="0.12169312169312169" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3278817860687776" LOG_CI_START="-2.15734972238008" LOG_EFFECT_SIZE="-0.9147339681556513" ORDER="3" O_E="0.0" SE="1.4598372901572316" STUDY_ID="STD-Grylack-1978" TOTAL_1="20" TOTAL_2="22" VAR="2.1311249137336095" WEIGHT="10.57503237254808"/>
<DICH_DATA CI_END="7.556887736615264" CI_START="0.5293184362947282" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8783429704868428" LOG_CI_START="-0.2762829791588805" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="4" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Rowley-1978" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="7.385736895112943"/>
<DICH_DATA CI_END="0.9462864740581284" CI_START="0.22394257547588348" EFFECT_SIZE="0.4603409933283914" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.023977367542710674" LOG_CI_START="-0.6498633314479375" LOG_EFFECT_SIZE="-0.33692034949532407" ORDER="5" O_E="0.0" SE="0.3676485133834184" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.13516542939303758" WEIGHT="47.44456700717791"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3149262111557165" CI_END="1.3172085702609246" CI_START="0.33786402760192985" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6671112296612429" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="18" I2="23.950105221411718" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.11965454773446445" LOG_CI_START="-0.4712580451165609" LOG_EFFECT_SIZE="-0.1758017486910482" METHOD="MH" NO="2" P_CHI2="0.25150480326186875" P_Q="0.0" P_Z="0.24352819109336288" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="106" TOTAL_2="109" WEIGHT="100.0" Z="1.1662134130232837">
<NAME>All deaths</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.863869030063714" CI_START="0.028030348225378122" EFFECT_SIZE="0.22857142857142856" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.27041539218160193" LOG_CI_START="-1.552371506898266" LOG_EFFECT_SIZE="-0.640978057358332" ORDER="6" O_E="0.0" SE="1.070714047460185" STUDY_ID="STD-Egan-1976" TOTAL_1="35" TOTAL_2="40" VAR="1.1464285714285716" WEIGHT="26.140304081088296"/>
<DICH_DATA CI_END="1.7087631930653142" CI_START="0.39572935667244846" EFFECT_SIZE="0.8223185265438786" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.23268188070146545" LOG_CI_START="-0.4026017309623289" LOG_EFFECT_SIZE="-0.08495992513043173" ORDER="7" O_E="0.0" SE="0.3731687381959077" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.1392549071667259" WEIGHT="73.85969591891171"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8359477793699077" CI_END="0.9571775985593369" CI_START="0.10460990601656175" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.3164336559635377" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.019007474011703784" LOG_CI_START="-0.9804271880822308" LOG_EFFECT_SIZE="-0.49971733104696725" METHOD="MH" NO="3" P_CHI2="0.6583794346422338" P_Q="0.0" P_Z="0.041603786113219264" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="126" TOTAL_2="131" WEIGHT="99.99999999999999" Z="2.03746180147641">
<NAME>NEC-related deaths</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.2706629717000806" CI_START="0.007052206410830555" EFFECT_SIZE="0.12654320987654322" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.35615267785999166" LOG_CI_START="-2.1516749848337446" LOG_EFFECT_SIZE="-0.8977611534868766" ORDER="8" O_E="0.0" SE="1.4731103830134407" STUDY_ID="STD-Egan-1976" TOTAL_1="35" TOTAL_2="40" VAR="2.1700542005420056" WEIGHT="33.18482101705331"/>
<DICH_DATA CI_END="4.304726536702083" CI_START="0.011146319981382718" EFFECT_SIZE="0.21904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6339455675496006" LOG_CI_START="-1.9528684936542908" LOG_EFFECT_SIZE="-0.6594614630523452" ORDER="9" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Grylack-1978" TOTAL_1="20" TOTAL_2="22" VAR="2.308902691511387" WEIGHT="18.82009525272699"/>
<DICH_DATA CI_END="1.866369792378577" CI_START="0.12650969130584605" EFFECT_SIZE="0.4859154929577465" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27099769668718465" LOG_CI_START="-0.8978762039787871" LOG_EFFECT_SIZE="-0.31343925364580116" ORDER="10" O_E="0.0" SE="0.6866023152703158" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.4714227393345581" WEIGHT="47.99508373021969"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7258895907310388" CI_START="0.028043508843169453" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.23701300941512912" LOG_CI_START="-1.5521676477707167" LOG_EFFECT_SIZE="-0.6575773191777937" METHOD="MH" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.14967211631714886" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.4406905836619521">
<NAME>NEC-like enteropathies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7258895907310379" CI_START="0.028043508843169477" EFFECT_SIZE="0.22" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23701300941512893" LOG_CI_START="-1.5521676477707165" LOG_EFFECT_SIZE="-0.6575773191777937" ORDER="11" O_E="0.0" SE="1.050973574618056" STUDY_ID="STD-Grylack-1978" TOTAL_1="20" TOTAL_2="22" VAR="1.1045454545454545" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0374333629840036" CI_END="2.9721090458628425" CI_START="1.0047247195630242" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7280484448114504" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" I2="3.6082667397868105" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.47306473952585937" LOG_CI_START="0.0020470874767583892" LOG_EFFECT_SIZE="0.23755591350130886" METHOD="MH" NO="5" P_CHI2="0.3084194845680418" P_Q="0.0" P_Z="0.04804158905180106" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="159" WEIGHT="100.0" Z="1.9770003640056422">
<NAME>Colonization with resistant bacteria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.47957831689597" CI_START="1.099295405129198" EFFECT_SIZE="1.9557823129251701" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5415266158599132" LOG_CI_START="0.04111441269503327" LOG_EFFECT_SIZE="0.2913205142774732" ORDER="12" O_E="0.0" SE="0.29394460521940596" STUDY_ID="STD-Boyle-1978" TOTAL_1="49" TOTAL_2="50" VAR="0.08640343093759244" WEIGHT="80.92485549132948"/>
<DICH_DATA CI_END="4.300775662412528" CI_START="0.13497538857619001" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6335467894228853" LOG_CI_START="-0.8697454135788742" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="13" O_E="0.0" SE="0.8830412814596522" STUDY_ID="STD-Egan-1976" TOTAL_1="35" TOTAL_2="40" VAR="0.7797619047619047" WEIGHT="19.07514450867052"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="14" O_E="0.0" SE="0.0" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Enteral aminoglycoside versus control (randomized studies)</NAME>
<DICH_OUTCOME CHI2="5.491122985979324" CI_END="0.8788434836750315" CI_START="0.306908763562823" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5193503316066602" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="35" I2="45.3663666310151" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.05608846307046278" LOG_CI_START="-0.5129907104191485" LOG_EFFECT_SIZE="-0.2845395867448057" METHOD="MH" NO="1" P_CHI2="0.13917061940252762" P_Q="0.0" P_Z="0.014639883386325422" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="191" WEIGHT="100.0" Z="2.441166991109718">
<NAME>NEC</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1822494681562843" CI_START="0.09785797214020377" EFFECT_SIZE="0.3401360544217687" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.07270912731690526" LOG_CI_START="-1.00940378814122" LOG_EFFECT_SIZE="-0.46834733041215726" ORDER="15" O_E="0.0" SE="0.6356384830854235" STUDY_ID="STD-Boyle-1978" TOTAL_1="49" TOTAL_2="50" VAR="0.40403628117913826" WEIGHT="25.11302692511852"/>
<DICH_DATA CI_END="2.1275598503971165" CI_START="0.0069606577058937864" EFFECT_SIZE="0.12169312169312169" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3278817860687776" LOG_CI_START="-2.15734972238008" LOG_EFFECT_SIZE="-0.9147339681556513" ORDER="16" O_E="0.0" SE="1.4598372901572316" STUDY_ID="STD-Grylack-1978" TOTAL_1="20" TOTAL_2="22" VAR="2.1311249137336095" WEIGHT="12.108066553182145"/>
<DICH_DATA CI_END="7.556887736615264" CI_START="0.5293184362947282" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8783429704868428" LOG_CI_START="-0.2762829791588805" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="17" O_E="0.0" SE="0.6782329983125268" STUDY_ID="STD-Rowley-1978" TOTAL_1="50" TOTAL_2="50" VAR="0.45999999999999996" WEIGHT="8.45642743396848"/>
<DICH_DATA CI_END="0.9462864740581284" CI_START="0.22394257547588348" EFFECT_SIZE="0.4603409933283914" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="19" LOG_CI_END="-0.023977367542710674" LOG_CI_START="-0.6498633314479375" LOG_EFFECT_SIZE="-0.33692034949532407" ORDER="18" O_E="0.0" SE="0.3676485133834184" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.13516542939303758" WEIGHT="54.32247908773086"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2310959407562998" CI_END="1.3869012378882575" CI_START="0.12164679006056071" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.41074576531003293" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.14204553579044987" LOG_CI_START="-0.9148993464732231" LOG_EFFECT_SIZE="-0.3864269053413866" METHOD="MH" NO="2" P_CHI2="0.6307124150639227" P_Q="0.0" P_Z="0.1518136028282329" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="91" TOTAL_2="91" WEIGHT="100.0" Z="1.43315480274485">
<NAME>NEC-related deaths</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.304726536702083" CI_START="0.011146319981382718" EFFECT_SIZE="0.21904761904761905" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6339455675496006" LOG_CI_START="-1.9528684936542908" LOG_EFFECT_SIZE="-0.6594614630523452" ORDER="19" O_E="0.0" SE="1.5195073844872842" STUDY_ID="STD-Grylack-1978" TOTAL_1="20" TOTAL_2="22" VAR="2.308902691511387" WEIGHT="28.167394803403077"/>
<DICH_DATA CI_END="1.866369792378577" CI_START="0.12650969130584605" EFFECT_SIZE="0.4859154929577465" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27099769668718465" LOG_CI_START="-0.8978762039787871" LOG_EFFECT_SIZE="-0.31343925364580116" ORDER="20" O_E="0.0" SE="0.6866023152703158" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.4714227393345581" WEIGHT="71.83260519659692"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7258895907310388" CI_START="0.028043508843169453" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.22" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.23701300941512912" LOG_CI_START="-1.5521676477707167" LOG_EFFECT_SIZE="-0.6575773191777937" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.14967211631714886" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.4406905836619521">
<NAME>NEC-like enteropathies</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7258895907310379" CI_START="0.028043508843169477" EFFECT_SIZE="0.22" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23701300941512893" LOG_CI_START="-1.5521676477707165" LOG_EFFECT_SIZE="-0.6575773191777937" ORDER="21" O_E="0.0" SE="1.050973574618056" STUDY_ID="STD-Grylack-1978" TOTAL_1="20" TOTAL_2="22" VAR="1.1045454545454545" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0374333629840036" CI_END="2.9721090458628425" CI_START="1.0047247195630242" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7280484448114504" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="15" I2="3.6082667397868105" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.47306473952585937" LOG_CI_START="0.0020470874767583892" LOG_EFFECT_SIZE="0.23755591350130886" METHOD="MH" NO="4" P_CHI2="0.3084194845680418" P_Q="0.0" P_Z="0.04804158905180106" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="155" TOTAL_2="159" WEIGHT="100.0" Z="1.9770003640056422">
<NAME>Colonization with resistant bacteria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.47957831689597" CI_START="1.099295405129198" EFFECT_SIZE="1.9557823129251701" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.5415266158599132" LOG_CI_START="0.04111441269503327" LOG_EFFECT_SIZE="0.2913205142774732" ORDER="22" O_E="0.0" SE="0.29394460521940596" STUDY_ID="STD-Boyle-1978" TOTAL_1="49" TOTAL_2="50" VAR="0.08640343093759244" WEIGHT="80.92485549132948"/>
<DICH_DATA CI_END="4.300775662412528" CI_START="0.13497538857619001" EFFECT_SIZE="0.7619047619047619" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.6335467894228853" LOG_CI_START="-0.8697454135788742" LOG_EFFECT_SIZE="-0.11809931207799451" ORDER="23" O_E="0.0" SE="0.8830412814596522" STUDY_ID="STD-Egan-1976" TOTAL_1="35" TOTAL_2="40" VAR="0.7797619047619047" WEIGHT="19.07514450867052"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="24" O_E="0.0" SE="0.0" STUDY_ID="STD-Siu-1998" TOTAL_1="71" TOTAL_2="69" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>